Table 3.
Control group (n10) | Cr group (n10) | Ac group (n10) | Oral-Cr/Ac group (n10) | ip-Cr/Ac group (n10) | p value | |
---|---|---|---|---|---|---|
H&E morphometry | ||||||
Lung injury score | 2.2 ± 0.75 | 2.75 ± 0.5 | 13.3 ± 2.7b | 8.7 ± 1.6bd | 4.4 ± 1.5adf | < 0.001 |
Radial alveolar count | 39.4 ± 7.2 | 41.2 ± 5.4 | 19.4 ± 4.2b | 27.3 ± 5.4bc | 30.2 ± 4.3ad | < 0.001 |
Alveolar no./field | 207.6 ± 15.6 | 211.3 ± 21.4 | 142.3 ± 17.3b | 169.3 ± 23.5bc | 183.4 ± 19.6d | < 0.001 |
Mean linear intercept | 52.3 ± 8.3 | 49.2 ± 9.1 | 78.2 ± 11.2b | 64.2 ± 7.8c | 59.3 ± 10.2d | < 0.001 |
Masson’s trichrome morphometry | ||||||
Lung fibrotic score | 0.5 ± 0.25 | 0.75 ± 0.25 | 3.5 ± 0.5b | 2.5 ± 1bc | 1 ± 0.25df | < 0.001 |
Immunohistochemical morphometry | ||||||
Anti-BAX grade | 0.7 ± 0.25 | 0.9 ± 0.3 | 3.5 ± 0.5b | 2 ± 0.7ad | 1 ± 0.5df | < 0.001 |
Anti-Bcl2 grade | 3.4 ± 0.6 | 3.5 ± 0.25 | 1 ± 0.5b | 1.5 ± 1b | 2.85 ± 0.75df | < 0.001 |
Bcl2/BAX index | 4.8 ± 1.52 | 4.1 ± 1.12 | 0.32 ± 0.09b | 0.81 ± 0.21b | 2.86 ± 1.74bdf | < 0.001 |
One-way ANOVA, and Tukey HSD Post-hoc Test, p > 0.05: no significant differences, p < 0.05: significant differences.
ap < 0.05 versus control group.
bp < 0.001 significant versus control group.
cp < 0.05 versus Ac group.
dp < 0.001 significant versus Ac group.
ep < 0.05 versus oral-Cr/Ac group.
fp < 0.001 significant versus oral-Cr/Ac group.